{"id":2523,"date":"2014-06-10T11:58:18","date_gmt":"2014-06-10T01:58:18","guid":{"rendered":"https:\/\/orthocell.com\/us\/?p=2523"},"modified":"2021-09-16T15:03:24","modified_gmt":"2021-09-16T05:03:24","slug":"biotech-orthocell-looks-to-raise-8m-in-ipo","status":"publish","type":"post","link":"\/americas\/biotech-orthocell-looks-to-raise-8m-in-ipo\/","title":{"rendered":"Biotech Orthocell looks to raise $8m in IPO"},"content":{"rendered":"

Details of Orthocell’s upcoming ASX launch have been featured in the Australian Financial Review (AFR).<\/p>\n

An excerpt from the article:<\/p>\n

“Orthocell , a local biotechnology company that sells customised injectable human stem cell therapy for tendon injuries, is set to debut on the ASX in July as an $33 million company.<\/p>\n

Up to 20 million shares are on offer in the float, priced at $0.40 per share to raise a maximum of $8 million. If the full amount is raised there will be a total of 77.5 million shares in the company at listing, giving it a market capitalisation of $82.5 million.”<\/p>\n

Read the article HERE.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Details of Orthocell’s upcoming launch on the ASX has been featured in the Australian Financial Review (AFR).<\/p>\n","protected":false},"author":2,"featured_media":2621,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-2523","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-media"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t